Please use this identifier to cite or link to this item:
Title: Bezafibrate induces autophagy and improves hepatic lipid metabolism in glycogen storage disease type Ia
Authors: Waskowicz L.R.
Zhou J. 
Landau D.J.
Brooks E.D.
Lim A. 
Yavarow Z.A.
Kudo T.
Zhang H.
Wu Y. 
Grant S.
Young S.P.
Huat B.B. 
Yen P.M.
Koeberl D.D.
Issue Date: 2019
Publisher: Oxford University Press
Citation: Waskowicz L.R., Zhou J., Landau D.J., Brooks E.D., Lim A., Yavarow Z.A., Kudo T., Zhang H., Wu Y., Grant S., Young S.P., Huat B.B., Yen P.M., Koeberl D.D. (2019). Bezafibrate induces autophagy and improves hepatic lipid metabolism in glycogen storage disease type Ia. Human Molecular Genetics 28 (1) : 143-154. ScholarBank@NUS Repository.
Abstract: Glucose-6-phosphatase α (G6Pase) deficiency, also known as von Gierke's Disease or Glycogen storage disease type Ia (GSD Ia), is characterized by decreased ability of the liver to convert glucose-6-phosphate to glucose leading to glycogen accumulation and hepatosteatosis. Long-Term complications of GSD Ia include hepatic adenomas and carcinomas, in association with the suppression of autophagy in the liver. The G6pc-'/-' mouse and canine models for GSD Ia were treated with the pan-peroxisomal proliferator-Activated receptor agonist, bezafibrate, to determine the drug's effect on liver metabolism and function. Hepatic glycogen and triglyceride concentrations were measured and western blotting was performed to investigate pathways affected by the treatment. Bezafibrate decreased liver triglyceride and glycogen concentrations and partially reversed the autophagy defect previously demonstrated in GSD Ia models. Changes in medium-chain acyl-CoA dehydrogenase expression and acylcarnintine flux suggested that fatty acid oxidation was increased and fatty acid synthase expression associated with lipogenesis was decreased in G6pc-'/-' mice treated with bezafibrate. In summary, bezafibrate induced autophagy in the liver while increasing fatty acid oxidation and decreasing lipogenesis in G6pc-'/-' mice. It represents a potential therapy for glycogen overload and hepatosteatosis associated with GSD Ia, with beneficial effects that have implications for non-Alcoholic fatty liver disease.
Source Title: Human Molecular Genetics
ISSN: 09646906
DOI: 10.1093/hmg/ddy343
Appears in Collections:Elements
Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
Bezafibrate_Manuscript_5.8.18 Final.docx131.13 kBMicrosoft Word XML


Supplementary Material.docx2.48 MBMicrosoft Word XML




checked on Nov 22, 2020

Page view(s)

checked on Nov 20, 2020


checked on Nov 20, 2020

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.